

RPG LIFE SCIENCES LIMITED

26, M.I.D.C Land, Thane - Belapur Road, Navi Mumbai 400 705, India,
Phones : 8795 5400 / 5555 / 5399 / 5398, Fax : 2767 2646 / 2763 1062



October 23, 2012

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, G. Block
Bandra- Kurla Complex
Bandra (E)
Mumbai 400 051

Dear Sir,

Sub: Unaudited financial results for the quarter and half year ended September 30, 2012
(Scrip Symbol: RPGLIFE)

We submit herewith the unaudited financial results along with limited review report of the statutory auditors for the quarter and half year ended September 30, 2012. These results have been reviewed by the Audit Committee and have been approved and taken on record by Board of Directors at its meeting held on October 23, 2012.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited

Rajesh Shirambekar
Head - Legal & Company Secretary

Encl: As above




RPG LIFE SCIENCES LIMITED

25, M.I.D.C Land, Thane - Bolapur Road, Navi Mumbai 400 705, India.

Phones : 6785 5400 / 5555 / 5399 / 5398. Fax : 2767 2646 / 2763 1052

PART I STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th SEPTEMBER, 2012						
Particulars	3 months ended	3 months ended	3 months ended	6 months ended	6 months ended	Year ended
	30.9.2012	30.6.2012	30.9.2011	30.9.2012	30.9.2011	31.3.2012
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Income from Operations						
(a) Net Sales/Income from Operations (Net of Excise Duty)	5,706	5,472	5,118	11,176	10,170	10,923
(b) Other Operating Income	137	107	115	244	107	359
Total Income from Operations	5,843	5,579	5,233	11,422	10,357	19,282
2. Expenses						
(a) Cost of Materials Consumed	1,553	1,355	1,329	2,908	2,579	4,465
(b) Purchases of Stock-in-Trade	685	359	249	1,044	543	1,195
(c) Changes In Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(352)	140	(222)	(212)	(448)	(140)
(d) Employee Benefits Expense	1,551	1,227	1,381	2,778	2,507	4,999
(e) Depreciation and Amortisation Expense	240	237	256	477	504	1,022
(f) Other Expenses	1,939	1,850	1,860	3,789	3,604	6,948
Total Expenses	5,616	5,168	4,853	10,704	9,289	18,489
3. Profit from Operations before Other Income and Finance Costs	227	411	380	638	1,068	793
4. Other Income	(2)	42	(2)	40	0	69
5. Profit from Ordinary Activities before Finance Costs	225	453	378	678	1,076	862
6. Finance Costs	174	168	154	342	288	680
7. Profit from Ordinary Activities before Tax	51	285	224	336	788	174
8. Tax Expense (including Deferred Tax)	20	6	17	26	180	89
9. Net Profit for the period	31	279	207	310	608	85
10. Paid-up Equity Share Capital (Face Value Rs. 8 each)	1,323	1,323	1,323	1,323	1,323	1,323
11. Reserves excluding Revaluation Reserves (as per last audited Balance Sheet)						6,091
12. Earnings per Share (of Rs. 8 each) (not annualised):						
(a) Basic	0.18	1.60	1.25	1.87	3.68	0.51
(b) Diluted	0.18	1.69	1.25	1.87	3.67	0.51

PART II Select Information for the Quarter and Half Year ended 30th September, 2012						
Particulars	3 months ended	3 months ended	3 months ended	6 months ended	6 months ended	Year ended
	30.9.2012	30.6.2012	30.9.2011	30.9.2012	30.9.2011	31.3.2012
A PARTICULARS OF SHAREHOLDING						
1. Public Shareholding						
- Number of Shares	7,196,344	7,754,293	7,844,292	7,196,344	7,844,292	7,754,293
- Percentage of Shareholding	43.52	46.90	47.44	43.52	47.44	46.90
2. Promoters and Promoter Group Shareholding						
(a) Pledged/Encumbered						
- Number of Shares	-	-	-	-	-	-
- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	-	-	-	-	-	-
- Percentage of Shares (as a % of the total Share Capital of the company)	-	-	-	-	-	-
(b) Non-Encumbered						
- Number of Shares	9,338,897	8,780,948	8,690,949	9,338,897	8,690,949	8,780,948
- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	100.00	100.00	100.00	100.00	100.00	100.00
- Percentage of Shares (as a % of the total share capital of the company)	56.48	53.10	52.56	56.48	52.56	53.10



RPG LIFE SCIENCES LIMITED

25, M.I.D.C Land, Thane - Belapur Road, Navi Mumbai 400 705, India.

Phones : 0795 5400 / 5555 / 5399 / 5398, Fax : 2767 2646 / 2763 1062


Particulars	3 months ended 30.9.2012
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	-
Received during the quarter	11
Disposed of during the quarter	11
Remaining unsolved at the end of the quarter	-

Notes.

1. Standalone Statement of Assets and Liabilities

Particulars	(Rs. in lakhs)	
	As at 30.9.2012	As at 31.3.2012
A EQUITY AND LIABILITIES		
1. Shareholders' Funds		
(a) Share Capital	1,323	1,323
(b) Reserves and Surplus	6,401	6,091
Sub-total - Shareholders' Funds	7,724	7,414
2. Non-Current Liabilities		
(a) Long-term Borrowings	1,188	2,067
(b) Deferred Tax Liabilities (Net)	708	682
(c) Other Long-term Liabilities	749	721
(d) Long-term Provisions	118	118
Sub-total - Non-Current Liabilities	2,763	3,588
3. Current Liabilities		
(a) Short-term Borrowings	3,298	2,439
(b) Trade Payables	4,678	2,924
(c) Other Current Liabilities	2,093	1,688
(d) Short-term Provisions	84	237
Sub-total - Current Liabilities	10,153	7,288
TOTAL - EQUITY AND LIABILITIES	30,640	18,290
B ASSETS		
1. Non-Current Assets		
(a) Fixed Assets	11,416	10,997
(b) Long-term Loans and Advances	154	147
(c) Other Non-Current Assets	69	67
Sub-total - Non-Current Assets	11,639	11,211
2. Current Assets		
(a) Inventories	3,483	2,899
(b) Trade Receivables	4,299	3,009
(c) Cash and Bank Balances	70	56
(d) Short-term Loans and Advances	1,149	1,115
Sub-total - Current Assets	9,001	7,079
TOTAL - ASSETS	30,640	18,290

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 23rd October, 2012.
- The results for the quarter ended 30th September, 2012 have been subjected to limited review by the statutory auditors of the company.
- The company is exclusively engaged in pharmaceuticals segment.
- The company continues to invest strongly in building of brands to gain market share.
- The company continues to actively focus on the remedial measures towards regaining EU GMP certification in the ensuing inspection by the Ministry of Social and Family Affairs, Health and Consumer Protection, Hamburg, Germany (HMA) for the company's API facility at Navi Mumbai, Maharashtra which was not granted certification in December 2011, citing certain deficiencies. Consequently, some of the orders were cancelled for the quarter ended 31st March, 2012 adversely affecting the business of the company. The reinspection of the facility by HMA has since been confirmed for Q3 of the current financial year.
- Consequent to acquisition of additional shares of the company during the quarter by one of the subsidiaries of Swallow Associates Limited (SAL), a Promoter Group Company, the company has become a subsidiary of SAL with effect from 13th July, 2012 in terms of the provisions of sub-section (3) of Section 4 of the Companies Act, 1956. SAL along with its subsidiaries, now holds 52.64% of the paid-up share capital of the company as at 30th September, 2012.
- Figures for the prior periods have been regrouped where necessary.



For RPG Life Sciences Limited

Ajit Singh Chouhan
Managing Director
Mumbai, 23rd October, 2012



The Board of Directors
RPG Life Sciences Limited
RPG House
463, Dr. Annie Besant Road
Worli, Mumbai - 400 030

1. We have reviewed the results of RPG Life Sciences Limited (the 'company') for the quarter ended 30th September, 2012 and the statement of assets and liabilities as on that date which are included in the accompanying 'Statement of Standalone Unaudited Results for the quarter and half year ended 30th September, 2012' (the 'Statement'), except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management but have neither been reviewed nor been audited by us. The Statement has been prepared by the company pursuant to Clause 41 of the Listing Agreement with the Stock Exchanges in India, which has been Initialled by us for identification purposes. This Statement is the responsibility of the company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. We have only traced the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' in the Statement from the disclosures made by the management and are, therefore, not expressing a review opinion thereon.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards notified pursuant to the Companies (Accounting Standards) Rules, 2006 as per Section 211(3C) of the Companies Act, 1956 and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Lovelock & Lewes
Firm Registration No. 301056E
Chartered Accountants


Himanshu Goradia
Partner
Membership No. 45668

Mumbai, 23rd October, 2012